AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
14.55
-0.45 (-3.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
AnaptysBio Revenue
AnaptysBio had revenue of $30.02M in the quarter ending September 30, 2024, with 804.67% growth. This brings the company's revenue in the last twelve months to $57.17M, up 282.17% year-over-year. In the year 2023, AnaptysBio had annual revenue of $17.16M with 66.78% growth.
Revenue (ttm)
$57.17M
Revenue Growth
+282.17%
P/S Ratio
6.98
Revenue / Employee
$488,650
Employees
117
Market Cap
442.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InnovAge Holding | 786.51M |
| Ginkgo Bioworks Holdings | 217.95M |
| UroGen Pharma | 89.36M |
| Theravance Biopharma | 63.19M |
| Zevra Therapeutics | 24.49M |
| MeiraGTx Holdings | 13.93M |
| PureTech Health | 468.00K |
ANAB News
- 10 days ago - AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Benzinga
- 10 days ago - AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters
- 10 days ago - AnaptysBio abandons eczema drug development after mid-stage trial failure - Reuters
- 10 days ago - Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - GlobeNewsWire
- 6 weeks ago - Anaptys Announces Participation in November and December Investor Conferences - GlobeNewsWire
- 6 weeks ago - Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire
- 4 months ago - AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point - Seeking Alpha